Myomo Financials
Myomo (MYO) reported $40.9M in revenue for fiscal year 2025, up 25.7% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 10 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Sales growth is not yet self-funding, because cash burn and commercialization spending still rise alongside revenue.
Revenue reached$40.9M in FY2025 after$19.2M in FY2023, but the earlier margin improvement did not hold: operating margin worsened again as R&D and SG&A expanded faster than gross profit. With net loss at-$15.6M and operating cash flow at-$14.5M , the shortfall looks like real operating consumption rather than an accounting mismatch.
Gross margin stayed high at
Near-term liquidity still looks workable, with cash of
Financial Health Signals
Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Myomo's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Myomo scores -2.41, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($66.5M) relative to total liabilities ($27.2M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Myomo passes 3 of 9 financial strength tests. 1 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass, 1 of 2 efficiency signals pass.
Myomo reported a net loss of $15.6M while operations used $14.5M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
Myomo generated $40.9M in revenue in fiscal year 2025. This represents an increase of 25.7% from the prior year.
Myomo's EBITDA was -$12.6M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 132.7% from the prior year.
Myomo reported -$15.6M in net income in fiscal year 2025. This represents a decrease of 151.6% from the prior year.
Myomo earned -$0.37 per diluted share (EPS) in fiscal year 2025. This represents a decrease of 131.3% from the prior year.
Cash & Balance Sheet
Myomo recorded an outflow of $16.3M in free cash flow in fiscal year 2025, representing a cash shortfall after capex. This represents a decrease of 249.5% from the prior year.
Myomo held $14.1M in cash against $11.2M in long-term debt as of fiscal year 2025.
Not reported for fiscal year 2025.
Margins & Returns
Myomo's gross margin was 65.7% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is down 5.5 percentage points from the prior year.
Myomo's operating margin was -35.2% in fiscal year 2025, reflecting core business profitability. This is down 16.1 percentage points from the prior year.
Myomo's net profit margin was -38.1% in fiscal year 2025, showing the share of revenue converted to profit. This is down 19.1 percentage points from the prior year.
Myomo's ROE was -136.8% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 111.7 percentage points from the prior year.
Capital Allocation
Myomo invested $6.9M in research and development in fiscal year 2025. This represents an increase of 45.5% from the prior year.
Myomo invested $1.7M in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 28.1% from the prior year.
Not reported for fiscal year 2025.
MYO Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $43.3M | $40.9M+25.7% | $32.6M+69.2% | $19.2M+23.7% | $15.6M+12.3% | $13.9M+82.7% | $7.6M+97.6% | $3.8M+57.0% | $2.4M+56.8% | $1.6M+41.3% | $1.1M |
| Cost of Revenue | $149K | $109K-15.6% | $129K+98.0% | $65K-98.8% | $5.3M+4596.3% | $113K-75.3% | $457K-6.8% | $491K-7.5% | $530K+48.8% | $356K+26.3% | $282K |
| Gross Profit | $29.6M | $26.9M+16.0% | $23.2M+75.9% | $13.2M+28.6% | $10.3M-0.6% | $10.3M+106.9% | $5.0M+106.2% | $2.4M+40.9% | $1.7M+62.9% | $1.1M+28.3% | $821K |
| R&D Expenses | $6.5M | $6.9M+45.5% | $4.8M+81.0% | $2.6M+6.2% | $2.5M-2.9% | $2.6M+53.2% | $1.7M-4.6% | $1.7M-4.8% | $1.8M+5.0% | $1.8M+56.3% | $1.1M |
| SG&A Expenses | $13.9M | $14.0M+12.7% | $12.4M-34.1% | $18.8M+1.8% | $18.4M+2.3% | $18.0M+30.4% | $13.8M+20.5% | $11.5M+10.2% | $10.4M+77.9% | $5.8M+96.6% | $3.0M |
| Operating Income | -$11.7M | -$14.4M-132.0% | -$6.2M+24.6% | -$8.2M+22.9% | -$10.7M-3.9% | -$10.3M+2.2% | -$10.5M+2.7% | -$10.8M-2.5% | -$10.5M-60.8% | -$6.5M-99.9% | -$3.3M |
| Interest Expense | N/A | N/A | N/A | N/A | N/A | N/A | $219K+92.6% | $114K | N/A | N/A | N/A |
| Income Tax | $438K | $505K+38.0% | $366K+134.4% | $156K+123.1% | $70K-21.4% | $89K | N/A | N/A | N/A | $0 | $0 |
| Net Income | -$14.5M | -$15.6M-151.6% | -$6.2M+23.5% | -$8.1M+24.4% | -$10.7M-3.4% | -$10.4M+10.3% | -$11.6M-7.9% | -$10.7M-3.8% | -$10.3M+14.7% | -$12.1M-234.5% | -$3.6M |
| EPS (Diluted) | — | -$0.37-131.3% | -$0.16+42.9% | -$0.28 | -$1.52+19.6% | -$1.89 | N/A | N/A | N/A | N/A | N/A |
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
MYO Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $38.6M-8.5% | $42.2M+189.7% | $14.6M+43.5% | $10.2M-49.4% | $20.1M+36.6% | $14.7M+122.9% | $6.6M-20.3% | $8.3M-40.7% | $14.0M+742.8% | $1.7M |
| Current Assets | $27.6M-16.0% | $32.8M+140.2% | $13.7M+48.1% | $9.2M-51.7% | $19.1M+32.2% | $14.4M+134.9% | $6.1M-21.9% | $7.9M-43.1% | $13.8M+1107.7% | $1.1M |
| Cash & Equivalents | $14.1M-42.0% | $24.4M+254.7% | $6.9M+28.5% | $5.3M-65.6% | $15.5M+26.8% | $12.2M+174.1% | $4.5M-31.7% | $6.5M-49.5% | $13.0M+1525.7% | $797K |
| Inventory | $3.1M-1.4% | $3.2M+75.5% | $1.8M+28.8% | $1.4M+73.2% | $808K+14.3% | $707K+60.9% | $440K+71.6% | $256K+27.3% | $201K+144.0% | $82K |
| Accounts Receivable | $4.1M+7.1% | $3.8M+60.5% | $2.4M+25.7% | $1.9M-3.3% | $2.0M+111.9% | $925K+118.0% | $424K+11.0% | $382K+28.7% | $297K+159.4% | $115K |
| Total Liabilities | $27.2M+55.4% | $17.5M+213.5% | $5.6M+47.1% | $3.8M-18.9% | $4.7M+49.0% | $3.1M+1719.6% | $173K-90.7% | $1.9M+21.3% | $1.5M-92.0% | $19.2M |
| Current Liabilities | $8.3M-18.0% | $10.2M+85.7% | $5.5M+52.1% | $3.6M-15.9% | $4.3M+49.3% | $2.9M | N/A | $1.9M+24.9% | $1.5M-50.5% | $3.0M |
| Long-Term Debt | $11.2M0.0% | $11.2M | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $11.4M-53.9% | $24.7M+174.9% | $9.0M+41.4% | $6.4M-58.7% | $15.4M+33.2% | $11.6M+80.0% | $6.4M0.0% | $6.4M-48.4% | $12.4M+171.0% | -$17.5M |
| Retained Earnings | -$118.7M-15.1% | -$103.1M-6.4% | -$96.9M-9.2% | -$88.8M-13.7% | -$78.1M-15.3% | -$67.7M-20.6% | -$56.1M-23.9% | -$45.3M-29.5% | -$35.0M-52.9% | -$22.9M |
Not reported in any period shown, so not listed: Goodwill.
MYO Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$7.1M | -$14.5M-341.1% | -$3.3M+46.7% | -$6.2M+39.7% | -$10.2M-7.2% | -$9.5M-5.7% | -$9.0M+12.7% | -$10.3M-7.7% | -$9.6M-56.1% | -$6.2M-92.1% | -$3.2M |
| Capital Expenditures | $1.2M | $1.7M+28.1% | $1.4M+832.8% | $146K+30.4% | $112K-65.8% | $326K+613.5% | $46K-12.0% | $52K-59.0% | $127K+89.3% | $67K+3492.6% | $2K |
| Free Cash Flow | -$10.8M | -$16.3M-249.5% | -$4.7M+26.4% | -$6.3M+38.9% | -$10.3M-4.8% | -$9.9M-8.8% | -$9.1M+12.7% | -$10.4M-6.8% | -$9.7M-56.5% | -$6.2M-94.1% | -$3.2M |
| Investing Cash Flow | -$2.9M | -$7.1M-2814.8% | $260K+112.8% | -$2.0M-553.0% | -$311K+4.8% | -$326K-613.5% | -$46K+12.0% | -$52K+59.0% | -$127K-89.3% | -$67K-3492.6% | -$2K |
| Financing Cash Flow | $7.2M | $11.4M-45.4% | $20.9M+115.5% | $9.7M+2477.5% | $377K-97.1% | $13.2M-21.5% | $16.8M+101.7% | $8.3M+149.2% | $3.3M-81.8% | $18.4M+521.2% | $3.0M |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
MYO Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 |
|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 65.7%-5.5pp | 71.2%+2.7pp | 68.5%+2.6pp | 65.9%-8.5pp | 74.4%+8.7pp | 65.7%+2.7pp | 63.0%-7.2pp | 70.2%+2.6pp | 67.6%-6.8pp | 74.4% |
| Operating Margin | -35.2%-16.1pp | -19.1%+23.7pp | -42.8%+25.8pp | -68.6%+5.5pp | -74.1% | -138.5% | -281.3% | -430.8% | -420.1% | -296.8% |
| Net Margin | -38.1%-19.1pp | -19.1%+23.0pp | -42.1%+26.8pp | -68.9%+5.9pp | -74.9% | -152.5% | -279.2% | -422.1% | -776.0% | -327.8% |
| Return on Equity | -136.8%-111.7pp | -25.1%+65.0pp | -90.1%+78.5pp | -168.6%-101.3pp | -67.3%+32.7pp | -100.0%+66.7pp | -166.7%-6.2pp | -160.5%-63.3pp | -97.2% | N/A |
| Return on Assets | -40.4%-25.7pp | -14.7%+40.9pp | -55.5%+49.9pp | -105.5%-53.9pp | -51.6%+27.0pp | -78.6%+83.7pp | -162.3%-37.8pp | -124.6%-38.0pp | -86.6%+131.6pp | -218.1% |
| Current Ratio | 3.30+0.1x | 3.22+0.7x | 2.49-0.1x | 2.56-1.9x | 4.46-0.6x | 5.03 | N/A | 4.24-5.1x | 9.32+8.9x | 0.38 |
| Debt-to-Equity | 0.98+0.5x | 0.45-0.2x | 0.620.0x | 0.60+0.3x | 0.300.0x | 0.27+0.2x | 0.03-0.3x | 0.29+0.2x | 0.12 | N/A |
| FCF Margin | -39.7%-25.4pp | -14.3%+18.6pp | -32.8%+33.7pp | -66.5%+4.7pp | -71.3% | -119.7% | -270.8% | -398.2% | -399.0% | -290.5% |
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.
Similar Companies
Where Myomo Ranks
Frequently Asked Questions
What is Myomo's annual revenue?
Myomo (MYO) reported $40.9M in total revenue for fiscal year 2025. This represents a 25.7% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Myomo's revenue growing?
Myomo (MYO) revenue grew by 25.7% year-over-year, from $32.6M to $40.9M in fiscal year 2025.
Is Myomo profitable?
No, Myomo (MYO) reported a net income of -$15.6M in fiscal year 2025, with a net profit margin of -38.1%.
What is Myomo's EBITDA?
Myomo (MYO) had EBITDA of -$12.6M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does Myomo have?
As of fiscal year 2025, Myomo (MYO) had $14.1M in cash and equivalents against $11.2M in long-term debt.
What is Myomo's gross margin?
Myomo (MYO) had a gross margin of 65.7% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is Myomo's operating margin?
Myomo (MYO) had an operating margin of -35.2% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Myomo's net profit margin?
Myomo (MYO) had a net profit margin of -38.1% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Myomo's return on equity (ROE)?
Myomo (MYO) has a return on equity of -136.8% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Myomo's free cash flow?
Myomo (MYO) recorded an outflow of $16.3M in free cash flow during fiscal year 2025. This represents a -249.5% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Myomo's operating cash flow?
Myomo (MYO) recorded an outflow of $14.5M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Myomo's total assets?
Myomo (MYO) had $38.6M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Myomo's capital expenditures?
Myomo (MYO) invested $1.7M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Myomo spend on research and development?
Myomo (MYO) invested $6.9M in research and development during fiscal year 2025.
What is Myomo's current ratio?
Myomo (MYO) had a current ratio of 3.30 as of fiscal year 2025, which is generally considered healthy.
What is Myomo's debt-to-equity ratio?
Myomo (MYO) had a debt-to-equity ratio of 0.98 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Myomo's return on assets (ROA)?
Myomo (MYO) had a return on assets of -40.4% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Myomo's cash runway?
Based on fiscal year 2025 data, Myomo (MYO) had $14.1M in cash against an annual operating cash burn of $14.5M. This gives an estimated cash runway of approximately 12 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Myomo's Altman Z-Score?
Myomo (MYO) has an Altman Z-Score of -2.41, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Myomo's Piotroski F-Score?
Myomo (MYO) has a Piotroski F-Score of 3 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Myomo's earnings high quality?
Myomo (MYO) reported a net loss of $15.6M while operations used $14.5M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is Myomo?
Myomo (MYO) scores 46 out of 100 on our Financial Health Score, indicating moderate standing within its emerging companies peer group. The score is a 0-100 composite of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.